|1.||Gires, Olivier: 21 articles (02/2015 - 04/2003)|
|2.||Baeuerle, Patrick A: 15 articles (01/2015 - 04/2007)|
|3.||Lindhofer, Horst: 14 articles (07/2014 - 11/2005)|
|4.||Krishnakumar, Subramanian: 12 articles (09/2015 - 12/2004)|
|5.||Yamashita, Taro: 11 articles (11/2015 - 11/2007)|
|6.||Spizzo, Gilbert: 10 articles (09/2015 - 09/2006)|
|7.||Gastl, Guenther: 9 articles (09/2015 - 01/2008)|
|8.||Duan, Wei: 9 articles (02/2015 - 05/2011)|
|9.||Moldenhauer, Gerhard: 9 articles (01/2015 - 01/2005)|
|10.||Münz, Markus: 9 articles (01/2015 - 04/2003)|
06/01/2015 - "The present findings suggest that afatinib might be beneficial for patients bearing tumors with constitutively activated EGFR, to target chemo-resistant CD133/EpCAM-positive cancer stem cells."
10/22/2013 - "Despite some promising results, the assays relying on EpCAM capture have shown inconsistent sensitivity in clinical settings and often fail to detect CTCs in patients with metastatic cancer. "
01/01/2015 - "Our results revealed that EpApt-siEp potentially eradicated EpCAM positive cancer cells through CSC marker suppression and apoptosis, while sparing normal EpCAM negative adjacent cells. "
01/01/2014 - "To this purpose, EpCAM-positive CTCs were enriched by CellSearch platform the only FDA-cleared automated platform that quantifies tumor burden in peripheral blood and provides clinical evidence of predictive and prognostic value. "
06/01/2011 - "EpCAM-AAB-levels after first-line treatment appear to correlate with macroscopic tumor residuals after initial surgery."
|2.||Ovarian Neoplasms (Ovarian Cancer)
07/01/2014 - "The aim of this study was to evaluate the prognostic influence of epithelial cell adhesion molecule (EpCAM) in an unselected cohort of ovarian cancer (OC) patients. "
07/12/2011 - "This study provides insights in transcriptional regulation of epcam in ovarian cancer. "
12/01/2015 - "Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspects."
01/01/2015 - "The most frequently elevated genes in ovarian cancer (serous type) are EPCAM, KRT19 and MUC1. "
01/01/2014 - "Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells."
|3.||Breast Neoplasms (Breast Cancer)
04/01/2015 - "This study implicates the potential value of EpCAM as a molecular marker for breast cancer."
04/01/2015 - "Collectively, our study highlights a novel function for EpCAM in TGF-β1-induced EMT process and suggests that targeting of EpCAM may be an attractive strategy to treat breast cancer. "
02/01/2014 - "The purpose of this study was to investigate the clinicopathologic significance of EpCAM and Sox2 expression in breast cancer and to study their correlation during breast cancer progression. "
01/01/2014 - "We designed the present prospective trial to characterize CTCs as well as other circulating cell populations in blood samples from women with metastatic breast cancer without EpCAM-dependent enrichment and/or isolation technology. "
04/01/2013 - "Further study is required to define the molecular mechanism(s) of EpCAM signaling in breast cancer and to direct the rational development of molecular therapies targeting EpCAM."
09/01/2014 - "A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma."
05/01/2013 - "The aim of our study was to investigate EpCAM expression and its relationship with established prognostic features in prostate carcinoma. "
05/01/2013 - "Several studies investigated EpCAM expression in prostate carcinoma but none of them confirmed its prognostic role. "
04/18/2012 - "This preclinical study suggests that anti-EpCAM antibody conjugates with α-amanitin have the potential to be highly effective therapeutic agents for pancreatic carcinomas and various EpCAM-expressing malignancies."
01/01/2012 - "Moreover, EpCAMlow breast carcinoma cell lines with mesenchymal phenotype (MDA-MB-231, Hs578t) and inducible overexpression of EpCAM were used to study effects on proliferation, migration and in vivo growth. "
01/01/2011 - "Catumazumab, a bivalent antibody against CD3 and EpCAM, is effective in the treatment of neoplastic ascites. "
01/01/2015 - "All cell-free plasma samples were analyzed for sEpCAM levels with a sandwich ELISA system established and validated by a human recombinant EpCAM standard for measurements in ascites as biological matrix. "
06/01/2012 - "Also a distinct and continuous decrease of EpCAM-positive cells was observed in the ascites samples under treatment. "
06/01/2012 - "Ascites samples were also stained to identify and quantify cells, positive for EpCAM (epithelial cell adhesion molecule) and CD45. "
05/01/2004 - "All ascites samples tested had EpCAM-positive cells by flow cytometry. "
|6.||monoclonal antibody 17-1A (Edrecolomab)
|7.||Messenger RNA (mRNA)
|8.||human MT201 antibody (adecatumumab)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)